Displaying results 1 - 12 of 18
Relaunch of the MEP Friends of the Liver Group On-demand Webinar • Liver disease is now the leading cause of years of working life lost in Europe, after ischaemic heart disease. Liver diseases are generally avoidable or treatable if measures for prevention and early detection are properly implemented; achieving this would reduce premature morbidity and mortality, saving the lives of almost 300’000 people across Europe each year. The European Association for the Study of the Liver (EASL) is relaunching an interest group to raise awareness, put liver health higher on the political agenda and make policy recommendations.
Education at EASL • Description EASL aims to be the prime resource for education and professional development in hepatology and liver related research. EASL strives to reach the following goals: Provide state-of-the-art education programmes for physicians, scientists, and other professionals Disseminate scientific and clinical practice knowledge Promote multidisciplinarity Watch this session at the International Liver CongressTM 2022, to hear the EASL Educational Committee present ongoing educational activities and discuss future challenges to improve current offerings. We would love to hear your feedback, please take the survey and help us to reach our goal of being the leader for education in hepatology!
EASL Patient Synergies Roundtable Discussion: Improving the Lives of Liver Cancer Patients • Description For Digital Liver Cancer Summit 2021, 5-6 February, and on the occasion of World Cancer Day, 4 February, EASL held a discussion aiming to identify the needs of liver cancer patients and their families, and the best ways to accompany them. The Roundtable Discussion was an open interaction between scientists, patient representatives, and nurses on three topics identified by the EASL-affiliated patient associations of EASL Patient Synergies. Programme and learning objectives Session 1: Early diagnosis and risk factors of liver cancer Understand the importance of information, early diagnosis and prevention measurements, such as vaccination Learn more about the key recent accomplishments in the early detection of HCC Apprehend the challenges encountered with early detection of HCC Session 2: COVID-19 challenges and liver cancer care What improvements in patient support and promotion of connectedness have taken place during COVID for people living with a liver cancer diagnosis and how can we continue to provide these benefits moving forward? What kind of impact will this situation have on cancer patients? Session 3: The inequality of the burden of cancer in different European countries Present the inequality of cancer burden in different European countries, linking this to their causes (prevention and survival) Understand the differences in cancer survival (diagnosis and access to treatment) Faculty Maria Reig, BCLC group, Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain Pierre Nahon, Paris-Seine-Saint-Denis Hospital, France Isabelle Soerjomataram, International Agency for Research on Cancer (IARC), France Session 1: Early diagnosis and risk factors of liver cancer